NO801388L - Fremgangsmaate for fremstilling av en suspensjon av svekkede carcinoma-celler - Google Patents
Fremgangsmaate for fremstilling av en suspensjon av svekkede carcinoma-cellerInfo
- Publication number
- NO801388L NO801388L NO801388A NO801388A NO801388L NO 801388 L NO801388 L NO 801388L NO 801388 A NO801388 A NO 801388A NO 801388 A NO801388 A NO 801388A NO 801388 L NO801388 L NO 801388L
- Authority
- NO
- Norway
- Prior art keywords
- cells
- approx
- weakened
- stated
- carcinoma
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 31
- 201000009030 Carcinoma Diseases 0.000 title claims description 29
- 239000000725 suspension Substances 0.000 title claims description 5
- 239000000824 cytostatic agent Substances 0.000 claims description 53
- 238000002360 preparation method Methods 0.000 claims description 27
- 230000001085 cytostatic effect Effects 0.000 claims description 17
- 235000015097 nutrients Nutrition 0.000 claims description 17
- 238000004113 cell culture Methods 0.000 claims description 13
- 238000011534 incubation Methods 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 230000000877 morphologic effect Effects 0.000 claims description 5
- 206010003445 Ascites Diseases 0.000 claims description 2
- 238000005119 centrifugation Methods 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000003860 storage Methods 0.000 claims description 2
- 239000001963 growth medium Substances 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 74
- 238000011282 treatment Methods 0.000 description 48
- 206010028980 Neoplasm Diseases 0.000 description 35
- 239000000243 solution Substances 0.000 description 35
- 238000012360 testing method Methods 0.000 description 20
- 210000001519 tissue Anatomy 0.000 description 17
- 239000006285 cell suspension Substances 0.000 description 16
- 201000011510 cancer Diseases 0.000 description 14
- 239000012588 trypsin Substances 0.000 description 13
- 102000004142 Trypsin Human genes 0.000 description 12
- 108090000631 Trypsin Proteins 0.000 description 12
- 239000012154 double-distilled water Substances 0.000 description 12
- 230000035945 sensitivity Effects 0.000 description 12
- 206010033128 Ovarian cancer Diseases 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 210000000481 breast Anatomy 0.000 description 7
- 230000000306 recurrent effect Effects 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 210000001015 abdomen Anatomy 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000825 pharmaceutical preparation Substances 0.000 description 5
- 239000011550 stock solution Substances 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- CPTIBDHUFVHUJK-NZYDNVMFSA-N mitopodozide Chemical compound C1([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H](CO)[C@@H]2C(=O)NNCC)=CC(OC)=C(OC)C(OC)=C1 CPTIBDHUFVHUJK-NZYDNVMFSA-N 0.000 description 4
- 229950010088 mitopodozide Drugs 0.000 description 4
- 239000013049 sediment Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 4
- 229960004528 vincristine Drugs 0.000 description 4
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 201000008275 breast carcinoma Diseases 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000012984 antibiotic solution Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 210000004303 peritoneum Anatomy 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 230000003319 supportive effect Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 230000003313 weakening effect Effects 0.000 description 2
- 208000006678 Abdominal Neoplasms Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 210000000712 G cell Anatomy 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 206010027452 Metastases to bone Diseases 0.000 description 1
- 206010059282 Metastases to central nervous system Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000011281 clinical therapy Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000009607 mammography Methods 0.000 description 1
- 210000001537 mesocolon Anatomy 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000002747 omentum Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000003415 peat Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000001931 thermography Methods 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 208000012991 uterine carcinoma Diseases 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 229940072358 xylocaine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/13—Tumour cells, irrespective of tissue of origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Developmental Biology & Embryology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19792918927 DE2918927A1 (de) | 1979-05-10 | 1979-05-10 | Arzneipraeparat zur behandlung von carcinomen und verfahren zu dessen herstellung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO801388L true NO801388L (no) | 1980-11-11 |
Family
ID=6070441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO801388A NO801388L (no) | 1979-05-10 | 1980-05-09 | Fremgangsmaate for fremstilling av en suspensjon av svekkede carcinoma-celler |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP0019167B1 (OSRAM) |
| JP (1) | JPS55151515A (OSRAM) |
| AT (1) | AT369653B (OSRAM) |
| AU (1) | AU5806980A (OSRAM) |
| CA (1) | CA1139219A (OSRAM) |
| CH (1) | CH647152A5 (OSRAM) |
| DD (1) | DD150545A5 (OSRAM) |
| DE (2) | DE2918927A1 (OSRAM) |
| DK (1) | DK189580A (OSRAM) |
| ES (1) | ES491356A0 (OSRAM) |
| FI (1) | FI801420A7 (OSRAM) |
| FR (1) | FR2455891A1 (OSRAM) |
| GB (1) | GB2048069B (OSRAM) |
| GR (1) | GR68513B (OSRAM) |
| IL (1) | IL59833A0 (OSRAM) |
| IT (1) | IT1133086B (OSRAM) |
| NO (1) | NO801388L (OSRAM) |
| PL (1) | PL224116A1 (OSRAM) |
| PT (1) | PT71195B (OSRAM) |
| ZA (1) | ZA802391B (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3432714A1 (de) * | 1984-09-06 | 1986-04-24 | Behringwerke Ag, 3550 Marburg | Tumortherapeutikum und verfahren zu seiner herstellung |
| DE3806565A1 (de) * | 1988-03-01 | 1989-09-14 | Deutsches Krebsforsch | Virusmodifizierte tumorvakzinen fuer die immuntherapie von tumormetastasen |
| WO1992010198A1 (en) * | 1990-12-06 | 1992-06-25 | Johnson & Johnson Research Pty Limited | Immunotherapeutic agents, compositions and methods |
| SE9604581D0 (sv) * | 1996-12-12 | 1996-12-12 | Karolinska Innovations Ab | An agent against cancer and virus infections |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2024458A1 (en) * | 1970-05-20 | 1971-12-02 | Hartmann geb. Ungewitter, Philippine, Dr., 8000 München | Tumour antigen - modified and potentiated by irradiation |
| DE2643215A1 (de) * | 1976-09-25 | 1978-04-06 | Bayer Ag | Cancerostatisch wirksame praeparationen aus tumorzellen und ein verfahren zu ihrer herstellung |
| DE2802277A1 (de) * | 1978-01-19 | 1979-08-02 | Jaeger Karl Heinz Dr Med | Verfahren zur herstellung eines gegen boesartiges wachstum gerichteten immunologischen wirkstoffkomplexes aus zellen |
-
1979
- 1979-05-10 DE DE19792918927 patent/DE2918927A1/de not_active Withdrawn
-
1980
- 1980-04-15 GB GB8012348A patent/GB2048069B/en not_active Expired
- 1980-04-15 IL IL59833A patent/IL59833A0/xx unknown
- 1980-04-21 ZA ZA00802391A patent/ZA802391B/xx unknown
- 1980-04-28 CA CA000350795A patent/CA1139219A/en not_active Expired
- 1980-04-30 DK DK189580A patent/DK189580A/da unknown
- 1980-05-02 FI FI801420A patent/FI801420A7/fi not_active Application Discontinuation
- 1980-05-02 GR GR61842A patent/GR68513B/el unknown
- 1980-05-02 DE DE8080102400T patent/DE3065252D1/de not_active Expired
- 1980-05-02 EP EP80102400A patent/EP0019167B1/de not_active Expired
- 1980-05-05 AU AU58069/80A patent/AU5806980A/en not_active Abandoned
- 1980-05-06 AT AT0240280A patent/AT369653B/de not_active IP Right Cessation
- 1980-05-06 CH CH3510/80A patent/CH647152A5/de not_active IP Right Cessation
- 1980-05-07 PT PT71195A patent/PT71195B/pt unknown
- 1980-05-08 PL PL22411680A patent/PL224116A1/xx unknown
- 1980-05-09 JP JP6082680A patent/JPS55151515A/ja active Pending
- 1980-05-09 NO NO801388A patent/NO801388L/no unknown
- 1980-05-09 FR FR8010400A patent/FR2455891A1/fr active Granted
- 1980-05-09 IT IT67731/80A patent/IT1133086B/it active
- 1980-05-09 DD DD80221015A patent/DD150545A5/de unknown
- 1980-05-09 ES ES491356A patent/ES491356A0/es active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| PT71195B (en) | 1981-09-17 |
| DE3065252D1 (en) | 1983-11-17 |
| DK189580A (da) | 1980-11-11 |
| DD150545A5 (de) | 1981-09-09 |
| CA1139219A (en) | 1983-01-11 |
| FI801420A7 (fi) | 1980-11-11 |
| IL59833A0 (en) | 1980-06-30 |
| IT1133086B (it) | 1986-07-09 |
| GB2048069B (en) | 1983-05-25 |
| EP0019167B1 (de) | 1983-10-12 |
| DE2918927A1 (de) | 1980-11-20 |
| ZA802391B (en) | 1981-04-29 |
| FR2455891A1 (fr) | 1980-12-05 |
| ES8200228A1 (es) | 1981-11-16 |
| CH647152A5 (de) | 1985-01-15 |
| FR2455891B1 (OSRAM) | 1983-12-30 |
| JPS55151515A (en) | 1980-11-26 |
| GR68513B (OSRAM) | 1982-01-11 |
| AT369653B (de) | 1983-01-25 |
| PT71195A (en) | 1980-06-01 |
| AU5806980A (en) | 1980-11-13 |
| ES491356A0 (es) | 1981-11-16 |
| PL224116A1 (OSRAM) | 1981-07-10 |
| ATA240280A (de) | 1982-06-15 |
| GB2048069A (en) | 1980-12-10 |
| IT8067731A0 (it) | 1980-05-09 |
| EP0019167A3 (en) | 1981-09-09 |
| EP0019167A2 (de) | 1980-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Buinauskas et al. | Role of operative stress on the resistance of the experimental animal to inoculated cancer cells | |
| US5126132A (en) | Tumor infiltrating lymphocytes as a treatment modality for human cancer | |
| HU205380B (en) | Simplified process for producing killer cells activated with human lymphokine | |
| NO861553L (no) | Angiogen faktor og fremgangsmaate for frembringelse av angiogenese. | |
| NO871978L (no) | Ekstrakter av nerium-arter, og fremgangsmaate for fremstilling av bruk av disse. | |
| CN106620681A (zh) | 一种细胞裂解液、试剂盒及在制备肿瘤全细胞抗原负载dc肿瘤疫苗中的应用 | |
| CN103417518B (zh) | 氧化白藜芦醇作为制备治疗肿瘤药物的应用 | |
| NO801388L (no) | Fremgangsmaate for fremstilling av en suspensjon av svekkede carcinoma-celler | |
| JP2020506183A (ja) | 造血幹細胞移植を受けている患者を治療するための便細菌叢 | |
| CN103127055A (zh) | 桔皮素作为制备治疗实体瘤化疗药物增敏剂的应用 | |
| Pearson et al. | ABO blood groups and toxaemia of pregnancy | |
| Kay et al. | A Foetal Tissue Bank | |
| Basset et al. | The “calcium-phosphate product” in an in vitro system of surviving bone | |
| COLE et al. | Differential inactivation of lymphocytes and bone marrow stem cells by heterologous anti-mouse γ-globulin serum | |
| Brynger et al. | Function of the duct-ligated canine pancreatic allograft | |
| Hellmann et al. | Localization of Tumours and Drugs on the Chorio-allantoic Membrane of the Chick Embryo | |
| RU2744846C1 (ru) | Способ лечения острой печёночной недостаточности | |
| Lincoln et al. | The treatment of primary tuberculosis in children | |
| Udekwu et al. | Studies of an alveolar soft tissue sarcoma | |
| RU2126973C1 (ru) | Способ коррекции нарушений фосфоинозитидного обмена | |
| Schechtman et al. | Culture of Brown-Pearce carcinoma in the embryonated egg | |
| CN108125968A (zh) | 一种虎杖苷在制备治疗及延缓椎间盘退行性病变药物中的应用 | |
| RU2457795C2 (ru) | Способ аутотрансплантации паращитовидных желез | |
| KR20220160987A (ko) | Nk 세포의 대량 증식 방법 | |
| Tong et al. | The Hong Kong Society of Dermatology and Venereology Annual Scientific Meeting 2013 |